PET scans may improve chemo decisions for abdominal cancer patients
NCT ID NCT06144853
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see if the scans could detect metabolic changes in tumors after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FDG-PET/CT scan
- What this could lead to
- If successful, this could show that PET scans are a useful tool to guide treatment decisions for people with abdominal cancer spread.
- What could go wrong
- This is a very small pilot study with only 34 participants, so results may not apply to everyone. It focuses on imaging, not on improving survival or symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABDOMINAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Odense PIPAC Center
Odense, Funen, 5000, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Your gut bacteria might reveal hidden cancer risk